Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma

[1]  D. Osoba,et al.  A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). , 2016 .

[2]  Laura W. Christianson,et al.  Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. , 2015, International journal of radiation oncology, biology, physics.

[3]  F. Dominici,et al.  Hospitalization burden and survival among older glioblastoma patients. , 2014, Neuro-oncology.

[4]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[5]  G. Reifenberger,et al.  MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.

[6]  N. Mohile,et al.  Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population. , 2014, American health & drug benefits.

[7]  D. Reardon,et al.  Treatment options and outcomes for glioblastoma in the elderly patient , 2014, Clinical interventions in aging.

[8]  J. King,et al.  Time trends in glioblastoma multiforme survival: the role of temozolomide. , 2013, Neuro-oncology.

[9]  R. Stupp,et al.  Optimal management of elderly patients with glioblastoma. , 2013, Cancer treatment reviews.

[10]  B. Stuart,et al.  Use and Spending on Antineoplastic Therapy for Medicare Beneficiaries With Cancer , 2013, Medical care.

[11]  Michael Weller,et al.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. , 2012, Neuro-oncology.

[12]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[13]  C. Gross,et al.  Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. , 2012, International journal of radiation oncology, biology, physics.

[14]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[15]  Dhruv B. Sharma,et al.  Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. , 2012, JAMA.

[16]  J. King,et al.  Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries , 2012, Cancer.

[17]  F. Ducray,et al.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Beroukhim,et al.  A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Menten,et al.  A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme , 2010 .

[20]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[21]  A. Brandes,et al.  Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma , 2009, Cancer.

[22]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[23]  Katherine S Panageas,et al.  Patterns of care in elderly glioblastoma patients , 2008, Annals of neurology.

[24]  V. Tombolini,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients , 2008, Journal of Neuro-Oncology.

[25]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[26]  Ralph B D'Agostino,et al.  Estimating treatment effects using observational data. , 2007, JAMA.

[27]  S. Preston‐Martin,et al.  A population‐based description of glioblastoma multiforme in Los Angeles County, 1974–1999 , 2005, Cancer.

[28]  R. Pazdur,et al.  Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme , 2005, Clinical Cancer Research.

[29]  R. Pazdur,et al.  U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[31]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Berger,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[33]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[34]  R. D'Agostino Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[35]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[36]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[37]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[38]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[39]  Jared K Lunceford,et al.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. , 2017, Statistics in medicine.

[40]  V. Esposito,et al.  Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. , 2015, International journal of radiation oncology, biology, physics.

[41]  A. Verma MGMT Gene Silencing and Benefit From Temozolomide in GlioblastomaHegi ME, Diserens A-C, Gorlia T, et al (Univ Hosp Lausanne, Switzerland; Univ Hosp Geneva; Swiss Inst for Experimental Cancer Research, Epalinges, Switzerland; et al) N Engl J Med 352:997–1003, 2005§ , 2006 .

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.